EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy

F M van den Tillaart iD, A Komrojan, C B Hoyng, J P Martinez Ciriano, S Yzer

Acta Ophthalmologica · 2025

DOI: 10.1111/aos.17511 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Ophthalmologica, 2025. Verfasst von F M van den Tillaart und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Photochemotherapy, Central Serous Chorioretinopathy, Visual Acuity, Verteporfin. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting voor Ooglijders, Stichting A.F. Deutman Oogheelkunde Researchfonds, Stichting Steunfonds Uitzicht.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate anatomical and functional outcomes after a second photodynamic therapy (PDT) in patients with central serous chorioretinopathy (CSC), who had a recurrence of subretinal fluid (SRF) after a previously successful PDT.

Methods

In this multicentre retrospective cohort study, we included patients with CSC who underwent a second PDT because of a recurrence of SRF after an effective first PDT with complete SRF resolution. Diagnosis of CSC was based on multimodal imaging. We evaluated the complete resolution rate of SRF after a second PDT with reduced settings. Also, visual acuity (VA), subfoveal ellipsoid zone (EZ) and subfoveal external limiting membrane (ELM) integrity before and after the first and the second PDT were studied.

Results

A total of 88 patients were studied, of whom 18% were female. The mean age was 51.3 ± 10.5 years at the second PDT. At the first follow‐up visit after the second PDT (median of 44 days [IQR 40–51] after PDT), a complete resolution of SRF occurred in 64% of eyes. The median VA was 0.15 LogMAR before the second PDT and improved to 0.05 LogMAR ( p < 0.001) after PDT. The EZ was continuous in 3% of patients before the second PDT, and EZ continuity increased to 27% at the first follow‐up visit after PDT. No new atrophy was observed after the second PDT.

Conclusion

A second PDT with reduced settings in recurrent CSC is effective and safe in the short term, as significant anatomical and functional improvement was observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyCentral Serous ChorioretinopathyVisual AcuityVerteporfinHumansFemaleRetrospective StudiesMiddle AgedPhotosensitizing AgentsTomography, Optical CoherenceMaleFluorescein AngiographyRecurrenceTreatment OutcomeFollow-Up StudiesFundus OculiAdultSubretinal Fluid

Stichwörter der Autor:innen

central serous chorioretinopathymultimodal imagingphotodynamic therapyrecurrencerepeated photodynamic therapysubretinal fluid

Substanzen

Photosensitizing AgentsVerteporfin

Autor:innen und Institutionen

  • Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Rotterdam Ophthalmic Institute, Rotterdam Eye Hospital, Rotterdam, The Netherlands.

ORCID-Profile: F M van den Tillaart

Förderung

  • Stichting voor Ooglijders
  • Stichting A.F. Deutman Oogheelkunde Researchfonds
  • Stichting Steunfonds Uitzicht

Zitieren

APA

van den Tillaart, F. M., Komrojan, A., Hoyng, C. B., Martinez Ciriano, J. P., & Yzer, S. (2025). Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy. Acta Ophthalmologica. https://doi.org/10.1111/aos.17511

Vancouver

van den Tillaart FM, Komrojan A, Hoyng CB, Martinez Ciriano JP, Yzer S. Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy. Acta Ophthalmologica. 2025. doi:10.1111/aos.17511

BibTeX
@article{vandenTillaart2025,
  author = {van den Tillaart, F M and Komrojan, A and Hoyng, C B and Martinez Ciriano, J P and Yzer, S},
  title = {Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy},
  journal = {Acta Ophthalmologica},
  year = {2025},
  doi = {10.1111/aos.17511}
}
Kostenlos starten →